65,437 trials
Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Comparison of Percentage of Complete Responders — 53.1; 59.2; 46.9; 40.8 percentage of participants — p=0.2344
Diabetes Mellitus, Insulin-Dependent · Hypercholesterolemia
Primary: LDL-C Levels Assessed at Randomization and 6 Months — 128; 87; 126; 133 mg/dL — p=<0.0001
Hypotension, Orthostatic
Primary: Time to Onset of Near-syncopal Symptoms During Tilt Table Testing — 551.3; 461.0 seconds — p=0.1460
Chronic HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 88.6; 90.6; 81.8 percentage of participants
Acquired Immune Deficiency Syndrome Virus
Primary: Percentage Change in Immune Activation Levels After 12 Weeks of Atorvastatin 80mg Daily — 60; 21 percentage change in activated T-cells — p=<0.05
Hypertension
Primary: Adverse Events — 47.8 percentage of participants
Healthy Volunteers
Primary: Pharmacokinetic Parameter: Area Under the Serum Insulin Concentration Versus Time Curve From Zero to Time of Return to Baseline (AUC0-tlast) — 2200; 2230…
Atrial Fibrillation
Primary: Number of Patients With at Least One Inappropriate MAI Criterion — 61; 11; 17 participants
Persian Gulf Syndrome
Primary: SF-36P — 73.7; 64.3 units on a scale — p=0.03
Dyslipidemia
Primary: Total Cholesterol Before and After Simvastatin/Ezetimibe Administration — 255; 253; 180; 215 mg/dl — p=<0.05
Endometrial Adenocarcinoma · Recurrent Endometrial Carcinoma · Stage IV Endometrial Carcinoma
Primary: Tumor Response — 12 percentage of participants
Non-small Cell Lung Cancer
Primary: Tumor Response by Direct RECIST Measurement — 0 participants
Asthma
Primary: Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period — 0.38; 1.30 L*hr — p=<0.0001
Head and Neck Cancer
Primary: Number of Participants Demonstrating the Safety and Tolerability of Long Term Erlotinib Treatment — 26; 22; 22; 6 participants
H7N9 Influenza
Primary: Geometric Mean Titers Of Subjects After Each Vaccination Of a Cell-Culture Derived H7N9c Monovalent Vaccine, Hemagglutination Inhibition Assay (Day 43) — 5; 5; 5; 5.05…